Alcon Inc.
HealthcareNYSE:ALC · New York Stock Exchange
+$0.18 today
Vol 0.76M · Avg 1.93M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
4.4%
avg 1.1%
ROIC
3.9%
avg 1.3%
ROA
3.1%
avg 0.8%
Analysis
ROE is currently the strongest return metric at 4.4% versus its period average of 1.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David J. Endicott | Chief Executive Officer & Director | $4.07M | — | 61 | — | — |
Daniel Cravens | Vice President of Investor Relations | — | — | — | — | — |
Leon Sergio Duplan Fraustro | Senior Vice President & President of Americas | — | — | 58 | — | — |
Royce R. Bedward | Senior Vice President, General Counsel & Corporate Secretary | — | — | 60 | — | — |
Timothy C. Stonesifer | Senior Vice President & Chief Financial Officer | — | — | 59 | — | — |
Kimberly Martin | Senior VP and Chief HR & Corporate Communications | — | — | 51 | — | — |
Ian Bell | Senior Vice President & Chief Operating Officer | — | — | 55 | — | — |
Muru Murugappan | Senior Vice President and Chief Information & Transformation Officer | — | — | — | — | — |
Franck Leveiller | SVP of Global Research & Development and Chief Scientific Officer | — | — | — | — | — |
Margaret Buckley | Chief Accounting Officer | — | — | — | — | — |
Laurent Attias | Senior VP of Corporate Strategy, Business Development and Licensing (BD&L), M&A | — | — | 58 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | +4.4% | +5.7% (11yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Recent growth has been strongest in Revenue at +4.4% over three years. Forward estimates point to Revenue at +5.7% (11yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Becton, Dickinson and Company
NYSE:BDX
$52.84B
Cardinal Health, Inc.
NYSE:CAH
$52.46B
Humana Inc.
NYSE:HUM
$45.39B
Agilent Technologies, Inc.
NYSE:A
$36.57B
IQVIA Holdings Inc.
NYSE:IQV
$29.88B
GE HealthCare Technologies Inc.
NASDAQ:GEHC
$29.52B
ResMed Inc.
NYSE:RMD
$28.07B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.26B
Mettler-Toledo International Inc.
NYSE:MTD
$22.83B
Insmed Incorporated
NASDAQ:INSM
$21.22B
Who manages ALC?
Alcon Inc. (ALC) lists 11 active executives. The top listed executive is Daniel Cravens, Vice President of Investor Relations.
Explore More
Continue the stock analysis
Jump to another research area for this company.